Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 26(114), 2017

DOI: 10.1073/pnas.1620013114

Elsevier, Obesity Research and Clinical Practice, 3(13), p. 296, 2019

DOI: 10.1016/j.orcp.2018.11.173

Links

Tools

Export citation

Search in Google Scholar

Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Significance Myostatin, via activation of the Smad2/3 pathway, has long been recognized as the body’s major negative regulator of skeletal muscle mass. In this study, however, we demonstrate that other TGF-β proteins, particularly activin A and activin B, act in concert with myostatin to repress muscle growth. Preventing activin and myostatin signaling in the tibialis anterior muscles of mice resulted in massive hypertrophy (>150%), which was dependent upon both the complete inhibition of the Smad2/3 pathway and activation of the parallel bone morphogenetic protein (BMP)/Smad1/5 axis. Using this approach in models of muscular dystrophy and cancer cachexia increased muscle mass or prevented muscle wasting, respectively, highlighting the potential therapeutic advantages of complete inhibition of Smad2/3 ligand activity in skeletal muscle.